Patients with autoimmune disorders may be cured with treatments that modulate the NF-κB pathway however, the overwhelming outcome of clinical trials on NF-κB selective compounds is for the moment non conclusive for autoimmune diseases (Table 3) (249). This evidence concerns the gene NFKB1 and Autoimmunity.